Biopharma Opportunities and Obligations
Gain insights on the value of public/private partnership in developing platforms for pandemic preparedness.
Improving Biomanufacturing Resilience
Understand new biopharma strategies and industry collaborations to achieve resilient biomanufacturing.
Resilience Index: New Findings
New findings reveal how government policy and regulation can build biopharma resilience.
Making policy work
To deliver life-saving drugs more quickly, biopharma must work in harmony with governments and regulators.
Flexfactory™ platform
Configurable biomanufacturing train designed for your current and future capacity needs.
KUBio™ facilities
Modular, turnkey biomanufacturing solutions for your capacity expansion.
KUBio™ box environments
Supporting rapid response demands for biomanufacturing capacity.
Aseptic filling
Standardized, closed, robotic aseptic filling workcells for filling drug products.
Figurate™ automation
Offering configurable platforms to connect your bioprocessing environment.
Bioprocess capacity solutions
Adapt to evolving biomanufacturing demands and rapid capacity needs with modular facilities and integrated, flexible manufacturing platforms.
Resource center
Featured article
Building biopharma resilience through education and training
Continuing education and additional job training are key to bridge biopharma skills gaps, grow talent and provide resilient biopharmaceutical supply chains. Read this article for new insights from NIBRT, Teesside University’s National Horizons Centre (NHC) and other leaders to learn how new approaches for talent sourcing and to fill specialized-skills gaps can grow biomanufacturing resilience.
Popular articles
Bridging the skills gap in biopharma
Understand how you can ensure your staff is up to date on today’s complex bioprocessing techniques and technologies.
Standardized approaches to biomanufacturing
Lower costs, improve outcomes and alter the landscape of the global pharmaceutical market.
Viral vector manufacturing: the key to the success of gene therapy
Understand current challenges and trends influencing design considerations for viral vector manufacturing facilities and how they can impact companies developing cell and gene therapies.
Staying flexible in biomanufacturing with optionality
The biopharma industry offers big rewards – but it poses big risks, too. Rather than fearing the unknown, the concept of optionality can help you better manage it.
mRNA production
Increasing mRNA capabilities and capacity for growing market needs.
Viral vector therapies
Designing agile manufacturing with an integrated drug substance/drug product ecosystem.